Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
29 September 2016Website:
http://www.fulgentgenetics.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:55:28 GMTDividend
Analysts recommendations
Institutional Ownership
FLGT Latest News
Fulgent Genetics, Inc. reported a quarterly loss of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.33. This is an improvement from the loss of $0.22 per share reported in the same quarter last year.
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Brandon Perthuis - CCO Paul Kim - CFO Lawrence Weiss - Chief Medical Officer Conference Call Participants David Westenberg - Piper Sandler Andrew Cooper - Raymond James Operator Hello, and welcome to the Fulgent Genetics Q3 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation.
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to earnings of $0.78 per share a year ago.
Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT's stock presents mixed signals with potential undervaluation, despite negative earnings forecasted till 2025. For Q2 earnings, monitor the core revenue performance, updates on reproductive health and oncology initiatives, and changes in cash reserves and debt.
We initiate our coverage of Fulgent Genetics with an "outperform" rating and a $42 target price for the next 12 months. The company is continuing its Phase 1 clinical trial evaluating the efficacy of FID-007, a nano-encapsulated paclitaxel, in treating various types of cancer.
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $4.93 per share a year ago.
If you're the type that runs toward danger, these stocks to buy may be right for you. To facilitate mobility, the enterprises on this list feature a market capitalization between $500 million to $2 billion.
Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.
What type of business is Fulgent Genetics?
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
What sector is Fulgent Genetics in?
Fulgent Genetics is in the Healthcare sector
What industry is Fulgent Genetics in?
Fulgent Genetics is in the Diagnostics & Research industry
What country is Fulgent Genetics from?
Fulgent Genetics is headquartered in United States
When did Fulgent Genetics go public?
Fulgent Genetics initial public offering (IPO) was on 29 September 2016
What is Fulgent Genetics website?
https://www.fulgentgenetics.com
Is Fulgent Genetics in the S&P 500?
No, Fulgent Genetics is not included in the S&P 500 index
Is Fulgent Genetics in the NASDAQ 100?
No, Fulgent Genetics is not included in the NASDAQ 100 index
Is Fulgent Genetics in the Dow Jones?
No, Fulgent Genetics is not included in the Dow Jones index
When does Fulgent Genetics report earnings?
The next expected earnings date for Fulgent Genetics is 02 August 2024